SLU-PP-915 is a synthetic small molecule from the Saint Louis University programme that produced SLU-PP-332.
Amounts reported for SLU-PP-915 are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No human amount or schedule has been recorded for this compound.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 2 preclinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical2 rows | |||||
| Discovery paper: gene expression and treadmill endurance in mice12-week-old male C57BL/6J mice on normal chow, 4 per group for gene expression and 6 per group for the running test | 20 mg/kg | A single injection for gene expression; dosed for 6 days before the treadmill test, which was run 1 hour after treatment | Intraperitoneal injection in a DMSO and Tween vehicle | Single dose, or 6 daysNot applicable | European Journal of Medicinal Chemistry (PubMed Central)2023 |
| One hour after a single dose, ERR target genes including PGC-1 alpha, PDK4 and DDIT4 were up in quadriceps muscle, and after six days of dosing mice ran longer and further to exhaustion than vehicle controls. The boronic acid replaced a phenol to improve stability in liver microsomes; the compound was selected over its siblings for potency, and Saint Louis University holds the intellectual property. | |||||
| Pressure-overload heart failure model in mice3-month-old male C57BL/6J mice given transaortic constriction, compared with sham and vehicle groups | 25 mg/kg per injection | Twice daily, at lights-on and lights-off | Intraperitoneal injection in a DMSO and Cremophor vehicle | 6 weeks from surgeryNot applicable | Circulation (PubMed)2024 |
| Both SLU-PP-915 and SLU-PP-332 improved ejection fraction, reduced fibrosis and increased survival after pressure overload without reducing cardiac hypertrophy, and the authors saw no overt toxicity at 25 mg/kg over the six weeks. Genetic experiments pointed to ERR gamma as the main mediator of the cardiac effect. This is a surgical heart failure model in mice, not evidence of a human effect. | |||||
| Community-reported1 row | |||||
| Vendor capsule listing | 10 mg per capsule, 60 capsules per bottle | Not stated | Oral capsule | Not stated | Community resource2026 |
| This is a vendor claim: the vendor lists SLU-PP-915 as 10 mg GMP capsules marked coming soon for exercise-mimetic pathway research and states no dosing. No human dose exists to compare it with; a straight per-kilogram conversion of the 20 mg/kg mouse dose would be 1.4 g for a 70 kg adult, and animal doses do not translate to people in any case. The capsule format also presumes oral absorption, which the 2026 paper reports in mice only. | |||||
Plus 1 community resource (a dosing guide, forum thread or vendor write-up), reported above but not linked.
SLU-PP-915 is a synthetic small molecule from the Saint Louis University programme that produced SLU-PP-332, designed as a pan-agonist of the three estrogen-related receptors that switch on mitochondrial and fatty acid oxidation genes in muscle and heart. Unlike SLU-PP-332 it carries a boronic acid group that gave it better metabolic stability and oral bioavailability, and in mice it has increased treadmill running capacity and protected the heart in a pressure-overload model of heart failure. Every published study is in mice or cells; there is no human study, no registered trial and no approval, yet it is listed by vendors as 10 mg capsules.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Energy balance, body composition and incretin signaling.
One hour after a single dose, ERR target genes including PGC-1 alpha, PDK4 and DDIT4 were up in quadriceps muscle, and after six days of dosing mice ran longer and further to exhaustion than vehicle controls. The.
Both SLU-PP-915 and SLU-PP-332 improved ejection fraction, reduced fibrosis and increased survival after pressure overload without reducing cardiac hypertrophy, and the authors saw no overt toxicity at 25 mg/kg over.
This is a vendor claim: the vendor lists SLU-PP-915 as 10 mg GMP capsules marked coming soon for exercise-mimetic pathway research and states no dosing. No human dose exists to compare it with; a straight per-kilogram.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
2 protocol rows describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
1 row record what blogs, vendor write-ups or forums describe for SLU-PP-915. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
SLU-PP-915, Compound 10s (in the discovery paper), CHEMBL5629871, HY-150244, CS-0649695
CKROIKQTGRZRKF-UHFFFAOYSA-N
[3-[5-[(2-fluorophenyl)carbamoyl]thiophen-2-yl]phenyl]boronic acid
4 curated references, each with its journal, year and study model, plus 1 community resource reported but not linked.